Please type a plus sign (+) inside this box +

Signature

PTO/SB/08A (08-00)

Approved for use through 10/31/2002, OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO					Complete if Known				
					Application Number	09/619,493			
INFO	RMATION	DIS	CLOSURE	Ì	Filing Date	July 19, 2000			
STAT	EMENT B	Y AF	PLICANT	Ī	First Named Inventor	N. NASHED et al.			
				[Group Art Unit	1616			
((use as many she	ets as	necessary)		Examiner Name	S.N. Qazi			
Sheet	1	of	2	abla	Attorney Docket Number	SCH 1686 C1	1		


U.S. PATENT DOCUMENTS U.S. Patent Document Date of Publication of Cited Document Name of Patentee or Applicant of Cited Document Kind Code Examin initials Cite No.1 Number (if known) MM-DD-YYYY <u>5_20</u>03 TECH CENTER 1600/2900 FOREIGN PATENT DOCUMENTS ages, Columns, Lines, Foreign Patent Docum Where Relevant
Passages or Relevant ate of Publication of Kingd Codes Name of Patentee or Applicant of Cited Document T° Cite No.1 Office³ Number⁴ **Cited Document** Figures Appear Examiner Data

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (08-00) -

Approved for use through 10/31/2002, OMB 0851-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE respond to a collection of information unless it contains a valid OMB control number

	Substitute f	or form 1449A/PT	ro		Complete If Known						
					Application Number	09/619,493	RECE	Ner			
INFORMATION DISCLOSURE					Filing Date	July 19, 2000					
	STATEMENT BY APPLICANT				First Named Inventor	N. NASHED et al.	0CT 1 5	1.			
					Group Art Unit	1616		2003			
	(use as many sh	heets as n	ecessary)	Examiner Name	S.N. Qazi	7011.00]			
	Sheet	2	of	2	Attomey Docket Number	SCH 1686 C1	CH CENTERA	600/200			
							1	000/290			

<u>:</u>	<u>:</u>	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials *	Cite No.	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.						
	B	E. Freeman et al., Evaluation of a Unique Oral Contraceptive in the Treatment of Premenstrual Dysphoric Disorder, Journal of Women's Heath & Gender-Based Medicine, Vol. 10, No. 6, 2001, pp. 561-569						
	B2	E. Freeman et al., A Double-blind Trial of Oral Progesterone, Alprazolam, and Placebo in Treatment of Severe Premenstrual Syndrome, JAMA, Vol. 274, No. 1, July 5, 1995, pp. 51-57						
	ВЗ	P.M. 'Brien et al., <i>Treatment of Premenstrual Syndrome by Spironolactone</i> , British Journal of Obstetrics and Gynaecology, Vol. 86, February 1979, pp. 142-147						
209	B	D. Hellberg et al., Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate, Int. J. Gynecol. Obstet., 1991; 34: pp. 243-248						
	B5	M. Wang et al., Treatment of premenstrual syndrome by spironolactone: A double-blind, placebo-controlled study, Acta Obstet Gynecol Scand. 1995: 74: pp. 803-808						
	В	R.B. Burnet et al., <i>Premenstrual Syndrome and Spironolactone</i> , Aust NZ J. Obstet Gynaecol 1991; 31: 4: 366						
	В	K. Aslasksen et al., Spironolactone in the Treatment of Premenstrual Tension: A Double- Blind Study of Spironolactone Versus Bendroflumethiazide and Placebo, Current Therapeutic Research, Vol. 49, No. 1, January 1991, pp. 120-130						
	\							

Examiner	Sahila	Qa,	Date	2/6/4
Signature	dauina	- 22	Considered	7/6/01

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Unique citation designation number. Applicant is to place a check mark here if English language Translation is attached.

Form PTO 1449 (Modified)	PATENT AND TRADEMARK OFFICE SCH 1686C1 09/619,493						
LIST OF	REFER	REDICES CITED BY AND	U CANT	APPLICANT Noi	man NASI	HED	
		SEP 2 5 2007 \$		FILING DATE July 19, 2000		GROUP	1616
		The PROPERTY OF		U.S. PATENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
3003	AA-	5,583,129	12/1996	Spona et al.			
2	AB					ļ	<u> </u>
	AC	,	ļ				
	AD				\		
	AE					L	
	AF				\rightarrow		
	AG					\	2001
	AH					<u> </u>)/2 8 00
	Al .		ļ				
	A.J						
	AK		<u> </u>				
			FO	REIGN PATENT DOCUMENTS			
		DOCUMENT NUMBER	DATE	COUNTRY		YE	TRANSLATION S NO
	AL	0 640 343 A	3/1/1995	EPO			
192	AM	43 13 926 A	11/3/1994	GERMANY			
-	AN	43 44 462 A	6/29/1995	GERMANY			
	AO						
	AP						
	AQ						
	AR		† <u>-</u>				
	AS						
		OTHER RE	FERENCES (Including Author, Title, Date, Pertin	ent Pages, e	tc.)	
<u> </u>				stract of Ain Shams Med, J. (1974), 2			
	AT						
5.03	AU	Boekler, H. (CA 78:2446	68, abstract o	f Sportarzt sportmad. (1972), 22(9), 23	33-4, 236-7, 1	972.	
1	AV	Neuman, Friedmund (C.	A 118:161077	7, abstract of Pharm. Ztg. (1992), 137((34), 9-15), 19	92.	
	AW	Guenther et al. (CA 113	:218253, abs	tract of WO 9004397), 1974.			
	AX	L.L. Altshuler et al.: "Pho 1995, pages 233-245	armacologica	management of premenstrual disord	er." HARVAR	D REV. PS	YCHIAT. , BD 2 nR. 5,
Examiner		Sabiha	, O	22		nsidered	7/7/04
*Examiner: In	itial if re	eference is considered, w	hether or not	citation is in conformance with MPEP with next communication to applicant	609; Draw lin	e through	citation if not in

Please type a plus sign (+) inside this box -> +

#9.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known **Application Number** 09/619,493 NFORMATION DISCLOSURE Filing Date July 19, 2000 STATEMENT BY APPLICANT N. Nashed et al. First Named Inventor 1616 Group Art Unit (use as many sheets as necessary) Examiner Name S. Qazi Attorney Docket Number SCH 1686 C1 of Sheet

					U.S. P	ATENT DOCUM	MENTS		
Examiner Initials *	Cite No.	U.S. Pat Number	ent Docur Kind Co (il know	ode ²	Name of F of C	ratentee or Applicant ited Document	Date of Publication of Cited Document MM-DID-YYYY	Pages, Columns, Lines, W Passages or Rele Figures Appea	here Relevant Ivani Ir
		1							
		1							
	,	1							
				_					
I								\	
								\	_
			\setminus						
$\Box I$									
-L								 \ \ 	
									
				-1					
					<u> </u>				
								\	_
	7				FOREIG	PATENT DOC	UMENTS		
	· /	For	eign Pate	ent Docur		Name of Patentee		of Pages, Columns, Lines Where Relevant	,
Examiner	Cite	V	-		ind Code ⁵	or Applicant of	Cited Documen		
Initials*	No.1	Office ³	Numb		ina Code If known)	Cited Document	MM-DD-YYYY	Passages or Relevent Figures Appear	T ₆
		 \ 	ı		1	\		1	
		 \ 	 -						
		 \	\vdash						Λ
		 \ 	 						\
	-	 \	 						
-		 				\			
		 '	/ 						1 7
		 	\		1		<i>Y</i> ·		11
		 	1		 				1
			///		L				
			-						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japenese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

TECH CENTER 1600/2900

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 6651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known Application Number 09/619,493 July 19, 2000 Filing Date N. Nashed et al. First Named Inventor 1616 **Group Art Unit Examiner Name** S. Qazi Attorney Docket Number SCH 1686 C1

(use as many sheets as necessary)

of 3 3 Sheet

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	tnclude name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
• •	BL /	Christine P. West, "Inhibition of ovulation with oral progestins-effectiveness in premenstrual syndrome," European Journal of Obstetrics & Gynecology and Reproductive Biology, 34 (1990), pp. 119-128	
	ВМ	C. Kirkham, MD., et al., "A Randomized, Doubte-Blind, Placebo-Controlled, Cross-Over Trial to Assess the Side Effects of Medroxyprogesterone Acetate In Hormone Replacement Therapy," Obstetrics & Gynecology, Vol. 78, No. 1, July 1991, pp. 93-97	
	BN	L. Dennerstein, et al., "Progesterone and premenstrual syndrome: a double blind crossover trial, "British Medical Journal, Vol. 290, June 1, 1985, pp. 1617-1621	
	во	Peter J. Schmidt, MD., et al., "Lack of Effect of Induced Menses on Symptoms in Women with Premenstrual Syndrome," The New England Journal of Medicine, Vol. 324, No. 17, April 25, 1991, pp. 1174-1179	
SOR	_BP \	John Bancroft et al., "The Impact of Oral Contraceptives on the Experience of Perimenstrual Mood, Clumsiness, Food Craving and Other Symptoms," Journal of Psychosomatic Research, Vol. 37, No. 2, 1993, pp. 195-202	
	Β̈Ω	Cynthia A. Graham, et al., "A Prospective Treatment Study of Premenstrual Symptoms Using a Triphasic Oral Contraceptive," Journal of Psychosomatic Research, Vol. 36, No. 3, 1992, pp. 257-268	
	BR	Lennart Nilsson et al., "Clinical Studies on Oral Contraceptives-a Randomized, Doubleblind, Crossover Study of 4 Different Preparations (Anoviar® mite, Lyndiol® mite, Ovulen®, and Volidan®)," Acta Obstetrichet Gynecologica Scandinavica," Vol. XLVI, Supplement 8, pp. 2-31	
	BŠ	Johan Cullberg, "Mood Changes and Menstrual Symptoms with Different Gestagen/Estrogen Combinations," Acta Psychiatrica Scandinavica, Supplementum 236, 1972, pp. 9-86	
` `	ВТ	Sam Silbergeld, Ph.D., MD., et al., "The Menstrual Cycle: A Double-Blind Study of Symptoms, Mood and Behavior, and Biochemical Variables Using Enovid and Placebo," Psychosomatic Medicine, Vol. 33, No. 5 (Sept-Oct 1971), pp. 411-428	
	-BU'.	Francis J. Kane, "latrogenic Depression in Women," Phenomenology and Treatment of Depression, Copyright 1977, pp. 69-81	

Examiner Signature	SABIHA GAZI	Date Considered	11/1	102
				· · · · · · · · · · · · · · · · · · ·

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

lease type a plus sign (+) inside this box	→	+
--	----------	---

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

titute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of 3

Complete if Known							
Application Number	09/619,493						
Filing Date	July 19, 2000						
First Named Inventor	N. Nashed et al.						
Group Art Unit	1616						
Examiner Name	S. Qazi						
Attorney Docket Number	SCH 1686 C1						

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS		4
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²	
	BAi	Mabray et al., "Treatment of Common Gynecologic-Endocrinologic Symptoms by Allergy Management Procedures," Obstetrics & Gynecology, Vol. 59, No. 5, May 1982, pp. 560-564		
SON	ВВ	B.P. Appleby, "A Study of Premenstrual Tension in General Practice," British Medical Journal, 2/6/60, pp. 391-393		
	ВС	Stuart L. Smith, "Mood and Menstrual Cycle," pp. 19-59		7
	3 BD	B. Andersch et al., "Progesterone Treatment of Premenstrual Tension-A Double Blind Study," Journal of Psychosomatic Research, Vol. 29, No. 5, 1985, pp. 489-493		
	BE \	Michael A. Richter, M.D., et al., "Progesterone Treatment of Premenstrual Syndrome," Current Therapeutic Research, Vol. 36, No. 5, Nov. 1984, pp. 840-850		
•	BF	Gwyneth A Sampson, "Premenstrual Syndrome: A Double-Blind Controlled Trial of Progesterone and Placebo," Brit. J. Psychiat. (1979), 135, 209-215		
CDD	BG	Sarah Maddocks, et al., "A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome," Am J Obstet Gynecol, March 1986, pp. 573-581		
300 2	ВН	Ellen Freeman, et al., "Ineffectiveness of Progesterone Suppository Treatment for Premenstrual Syndrome," JAMA, Vol. 264, No. 3, July 18, 1980, pp. 349-353		1
	BI	. Lorraine Dennerstein, et al., "Treatment of Premenstrual Syndrome a Double-blind Trial of Dydrogesterone," . Journal of Affective Disorders, 11 (1986), pp-199-205		1
	BJ	Gwyneth A. Sampson, et al., "Premenstrual Syndrome A Double-blind Cross-over Study of Treatment with Dydrogesterone and Placebo," British Journal of Psychiatry, 153 (1988), pp. 232-235		
	ВК	Pekka Ylostalo, et al., "Bromocriptine and Norethisterone in the Treatment of Premenstrual Syndrome," Obstetrics & Gynecology, Vol. 58, No. 3, March, 1982, pp. 292-298		

Examiner		<u> </u>	Date		C/12/
Signature	SABIHA	SAZI	Considered	11/1.	5/02

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.